Trigonelline (chloride)


CAS No. : 6138-41-6

(Synonyms: Trigonelline (hydrochloride))

6138-41-6
Price and Availability of CAS No. : 6138-41-6
Size Price Stock
1g $78 In-stock
5g $229 In-stock
10 g Get quote
50 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-N0415
M.Wt: 173.60
Formula: C7H8ClNO2
Purity: >98 %
Solubility: H2O : 100 mg/mL (ultrasonic);DMSO : 20.83 mg/mL (ultrasonic;warming;heat to 60°C)
Introduction of 6138-41-6 :

Trigonelline chloride is an alkaloid with potential antidiabetic activity that can be isolated from Trigonella foenum-graecum L or Leonurus artemisia. Trigonelline chloride is a potent Nrf2 inhibitor that blocks Nrf2-dependent proteasome activity, thereby enhancing apoptosis in pancreatic cancer cells. Trigonelline chloride also has anti-HSV-1, antibacterial, and antifungal activity, and induces ferroptosis. In Vitro: It is found that Trigonelline chloride (TG) significantly rescues the morphology of the H9c2 cells. Treatment of cells with Trigonelline chloride attenuates H2O2 induced cell deaths and improves the antioxidant activity. In addition, Trigonelline chloride regulates the apoptotic gene caspase-3, caspase-9 and anti-apoptotic gene Bcl-2, Bcl-XL during H2O2 induced oxidative stress in H9c2 cells. For evident, flow cytometer results also confirm that Trigonelline chloride significantly reduces the H2O2 induced necrosis and apoptosis in H9c2 cells[1]. In Vivo: Trigonelline chloride decreases bone mineralization and tends to worsen bone mechanical properties in streptozotocin-induced diabetic rats. In nicotinamide/streptozotocin-treated rats, Trigonelline chloride significantly increases bone mineral density (BMD) and tends to improve cancellous bone strength. Trigonelline chloride differentially affects the skeletal system of rats with streptozotocin-induced metabolic disorders, intensifying the osteoporotic changes in streptozotocin-treated rats and favorably affecting bones in the non-hyperglycemic (nicotinamide/streptozotocin-treated) rats[2].

Your information is safe with us.